Publications by authors named "Dean Fennell"

Claim this Profile
B
BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities.
Jasper H L T van Genugten, Dean A Fennell, Paul Baas

Oncogene· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction.
James R M Black, Takahiro Karasaki, Charles W Abbott, Bailiang Li, Selvaraju Veeriah, Dean A Fennell

Cell· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.
Jasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, Charlotte Poile, Lodewyk Wessels, Dean A Fennell

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pleural mesothelioma.
Dean A Fennell, Yoshitaka Sekido, Paul Baas, Aliya N Husain, Alessandra Curioni-Fontecedro

Nat Rev Dis Primers· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Dean A Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
Gary Middleton, Helen L Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi, Dean Fennell

NPJ Precis Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence and prognostic significance of Sarcopenia and Adipopenia in Pleural Mesothelioma.
Andrew C Kidd, Gordon W Cowell, Geoffrey A Martin, Jenny Ferguson, Dean A Fennell

Cancer Treat Res Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting DNA Damage Response Deficiency in Thoracic Cancers.
Aleksandra Bzura, Jake B Spicer, Sean Dulloo, Timothy A Yap, Dean A Fennell

Drugs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Min Zhang, Aleksandra Bzura, Essa Y Baitei, Zisen Zhou, Jake B Spicer, Dean A Fennell

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.
Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Dean Fennell

Lancet Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.
Alexander M Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L Lim, Takahiro Karasaki, Dean A Fennell

Nature· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Eric Lim, David Waller, Kelvin Lau, Jeremy Steele, Anthony Pope, Dean Fennell

Lancet Respir Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the pleural space for anticancer therapies in pleural mesothelioma.
Kevin G Blyth, Prasad S Adusumilli, Philippe Astoul, Liz Darlison, Y C Gary Lee, Dean A Fennell

Lancet Respir Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Peter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Dean A Fennell

JAMA Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways.
Maymun Jama, Min Zhang, Charlotte Poile, Apostolos Nakas, Annabel Sharkey, Dean A Fennell

Genes Chromosomes Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
Dean Fennell, Daniel Griffiths, Zina Eminton, Abigail Morgan-Fox, Kayleigh Hill

BMJ Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
Dean A Fennell

Lancet Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Family Matters: Germline Testing in Thoracic Cancers.
Feighanne Hathaway, Renato Martins, Steven Sorscher, Aleksandra Bzura, Frank Dudbridge, Dean A Fennell

Am Soc Clin Oncol Educ Book· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of non-small cell lung cancer metastases in TRACERx.
Maise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, Kristiana Grigoriadis, Thomas B K Watkins, Dean A Fennell

Nature· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Alexander M Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L Lim, Takahiro Karasaki, Dean A Fennell

Nature· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Anita Singh, Sara Busacca, Aarti Gaba, Michael Sheaff, Charlotte Poile, Dean A Fennell

Oncogene· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: determines mesothelioma cell fate to EZH2 inhibition.
Giulia Pinton, Zhuo Wang, Cecilia Balzano, Sara Missaglia, Daniela Tavian, Dean A Fennell

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
Dean A Fennell, Catharine Porter, Jason Lester, Sarah Danson, Fiona Blackhall

EClinicalMedicine· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy approaches for malignant pleural mesothelioma.
Dean A Fennell, Sean Dulloo, James Harber

Nat Rev Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating innovations in systemic therapy for pleural mesothelioma.
Dean A Fennell, Aleksandra Bzura

Nat Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis